PRPO Precipio

Filed: 21 Feb 05, 7:00pm
                                                                    Exhibit 99.1


    Simultaneous Analysis of DNA From Multiple Bacterial Species in a Single
                    Sample Facilitates Entry Into New Markets

     OMAHA, Neb., Feb. 22 /PRNewswire-FirstCall/ -- Transgenomic Inc. (Nasdaq:
TBIO) announced today that it has launched the WAVE(R) Microbial Analysis
System, which employs Temperature Modulated Fragment Analysis (TMFA), an
advancement of Denaturing High Performance Liquid Chromatography (DHPLC) that
was developed for automated culture-independent molecular analysis of mixed
microbial communities. This extension of the WAVE(R) System product line opens
new market opportunities and is the latest example of Transgenomic's commitment
to providing innovative solutions for researchers ongoing and varied needs.

     While WAVE Systems have most frequently been used to detect genetic
variations relative to a normal (or reference) copy of a gene of interest, this
new application capitalizes on an ability to separate several similarly- or
identically-sized DNA fragments that differ among bacterial species in their
exact DNA sequence. This produces an output on the WAVE System consisting of
distinct peak profiles, which facilitates identification of the various
individual species in the specimen from which the DNA was obtained. Importantly,
individual DNA fragments can be isolated following separation on the WAVE
System, enabling the DNA sequence analysis of specific fragments derived from
each species in a mixture. In contrast, existing strategies for the analysis of
mixed microbial communities (or infections) typically require labor-intensive
and time-consuming manual techniques that do not readily enable isolation and
further analysis of individual DNA fragments.

     Collin D'Silva, Transgenomic's CEO, commented, "We are pleased with the
positive feedback we have received from several early adopters of this
methodology. The WAVE Microbial Analysis System provides an example of the
utility of the Company's WAVE technology in solving a broad range of challenging
analytical problems, resulting in new market opportunities beyond our
traditional areas of strength. We believe this product line extension offers to
clinical microbiology researchers a unique solution for the molecular analysis
of complex infections involving multiple species of bacterial, fungal, viral or
parasitic pathogens. In addition, the WAVE Microbial Analysis System also offers
significant value in the detection and evaluation of microbial communities in a
variety of environmental settings."

     About Transgenomic
     Transgenomic provides versatile and innovative research tools and related
consumable products. Transgenomic's BioSystems segment offers its WAVE Systems
and associated consumables. These systems are specifically designed for use in
genetic variation detection and single- and double-strand DNA/RNA analysis and
purification. These systems have broad applicability to genetic research and
molecular diagnostics. To date there have been approximately one thousand
systems installed in over 30 countries around the world. In addition, the
BioSystems segment offers WAVE-based biomarker discovery and validation services
in support of translational research, pre-clinical and clinical studies. Through
its nucleic acids business segment, Transgenomic provides specialty chemicals,
including advanced nucleic acid building blocks and associated reagents used in
the manufacture of synthetic oligonucleotides. For more information about the
innovative genomics research tools developed and marketed by Transgenomic,
please visit the company's Web site at

     Forward-Looking Statement
     Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include, but
are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including statements regarding entry into new
markets. The known risks, uncertainties and other factors affecting these
forward-looking statements are described from time to time in Transgenomic's
reports to the Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and performance to
differ materially from those referred to in such statements. Accordingly, the
company claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking statements,
unless required by law.

SOURCE  Transgenomic Inc.
     -0- 02/22/2005
     /CONTACT: Mitchell L. Murphy, +1-402-452-5418,, or
Robert J. Pogulis, Ph.D., +1-845-782-9617,, both of
Transgenomic Inc./